EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
about
Epigenetics of lung cancersiRNA delivery to the lung: what's new?Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysisDevelopment of New Molecular EZH2 on Lung Cancer Invasion and MetastasisProgress of Long Non-coding RNAs in Non-small Cell Lung CancerPharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMSSilencing of advanced glycosylation and glycosylation and product-specific receptor (RAGE) inhibits the metastasis and growth of non-small cell lung cancerLong non-coding RNAs in non-small cell lung cancer as biomarkers and therapeutic targets.The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expressionImmunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkersPrognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma.Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery SystemsPrognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis.The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell CarcinomaThe polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.Epigenetic cancer prevention mechanisms in skin cancer.Long noncoding RNA HOTAIR involvement in cancer.Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer.Autophagy regulated by lncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells.The role of microRNA-26a in human cancer progression and clinical application.EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer.Screening of critical genes in lung adenocarcinoma via network analysis of gene expression profile.Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia.Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer.Histone code and long non-coding RNAs (lncRNAs) aberrations in lung cancer: implications in the therapy response.Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients.HOXD-AS1 functions as an oncogenic ceRNA to promote NSCLC cell progression by sequestering miR-147a.Expression and clinicopathological significance of Mel-18 mRNA in colorectal cancer.Nested quantitative PCR approach for urinary cell-free EZH2 mRNA and its potential clinical application in bladder cancer.miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells.Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications.Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
P2860
Q26996766-B664902D-A069-485F-8BFD-419FA21018B2Q27022043-DA5FB51F-BFDA-47DE-ABFF-CE89E188DC4BQ27853296-047E09EB-5217-4C2E-86BF-4E91870BEBDDQ28072419-4561779B-12D5-4AF1-9214-EC8D0EAD728CQ28074528-B7A30F6E-A8BD-499E-A8B1-03CF0DCE07F3Q33592489-D8099231-82AF-4705-A3DC-ECC57DA6A0EDQ33850230-B94BA598-0404-4852-AF85-421BDB4A79A4Q34998371-A819F6FF-69A9-4428-A523-5B754AD0C8C2Q35025421-69D30E40-057B-4477-B8E7-BE829770CB5AQ35151124-9984C491-5C48-4BD4-A08E-995675ABC7ACQ35870148-51ACDDD7-5E5C-4228-B52F-C38938CA45C0Q36341433-53907CBF-E1B0-4624-82E2-635422F4C6A4Q36453727-CF07F4F2-196B-4268-A007-B93A42160BBEQ36865026-E7745E4F-8325-4FF6-8B89-4DCB47F8DCEBQ37589165-D3320065-5910-4A8A-8E46-A09AB756780CQ38125641-E0FCD359-4257-4358-B275-A8DE4B5001BDQ38244306-92B41775-601F-41E9-95D3-41DCE4F8F58EQ38696030-071680DE-32AA-4958-97D3-4B405BF5DCF8Q38696862-0B34A7A6-4006-4C9D-89FE-713D0A6A0750Q38796729-A255221B-6BF4-4D55-8709-6599DEFEB10EQ39077650-843975B9-107C-439F-A614-143FDB7D0E38Q39186842-9CE0A0FF-514F-4107-BFCE-BB019B0A0088Q39900657-0CD4D320-8D34-4387-9B36-C8031FE6F840Q41083925-B221757B-3E4C-49BB-9511-F6201868B7F1Q41466279-5985D12C-EA4D-4816-9A3A-A52C0F384330Q42366529-EEEFF833-1F34-42D7-9298-4B58D05C560CQ42370600-FA4D75B2-0CD3-4B34-8071-222E284D3753Q44123472-511A195D-4C50-41FF-B324-3F4A193D88A9Q48200477-774218F1-A850-4D3E-AE64-44FBB9391883Q51502591-14FF9C90-D551-4E9C-8F34-41628D6B9588Q53048458-FFCC1458-C306-41D9-89BD-2452CA89C2DEQ53073353-D328DCB1-3B01-4801-901E-55194B77DB49Q54188074-08FA2B04-E8A1-44E3-A99D-EE1D44497E90
P2860
EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@ast
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@en
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@nl
type
label
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@ast
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@en
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@nl
prefLabel
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@ast
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@en
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@nl
P2093
P2860
P1433
P1476
EZH2 promotes malignant behavi ...... th non-small cell lung cancer.
@en
P2093
Hening Ren
Pierre Saintigny
Rachel de Oliveira Ribeiro
Ronghui Xia
Ruxian Lin
P2860
P304
P356
10.1371/JOURNAL.PONE.0052984
P407
P577
2012-12-31T00:00:00Z